A single 10 mcg implant administered intracamerally, under aseptic conditions, once per eye
One implant per eye for life: retreatment is contraindicated because of corneal endothelial cell loss
Contraindications
Ocular or periocular infections Corneal endothelial cell dystrophy Prior corneal transplantation Absent or ruptured posterior lens capsule Hypersensitivity.
Available Forms
10 mcg bimatoprost intracameral implant in a single-use applicator, in a sealed foil pouch.
Mechanism of Action
Bimatoprost, a prostaglandin analog, is a synthetic structural analog of prostaglandin with ocular hypotensive activity. Bimatoprost is believed to lower IOP in humans by increasing outflow of aqueous humor through both the trabecular meshwork (conventional) and uveoscleral routes (unconventional). Elevated IOP presents a major risk factor for glaucomatous field loss. The higher the level of IOP, the greater the likelihood of optic nerve damage and visual field loss.
Warnings & Precautions
Endothelial cell loss: because of possible corneal endothelial cell loss, administration is limited to a SINGLE implant per eye, with no retreatment.
Corneal adverse reactions: corneal endothelial cell loss, corneal edema and corneal decompensation have been reported.
Iridocorneal angles: use with caution in narrow angles or other angle abnormalities.
Macular oedema, including cystoid macular oedema, may occur.
Common Side Effects
the most common ocular adverse reaction reported by 27% of patients was conjunctival hyperemia.
Pregnancy & Lactation
Pregnancy: No adequate and well-controlled studies in pregnant women. Oral bimatoprost in animals produced adverse effects only at exposures far above the clinical one.
Lactation: Unknown whether bimatoprost is present in human milk.
Pediatric Use
Safety and effectiveness of DURYSTA in pediatric patients have not been established.
GoodRx
Available Forms
Mechanism of Action
Pregnancy & Lactation
Pediatric Use